Get the Stockscreener App
9.485
0.37%
-0.035
Ocular Therapeutix Inc stock is traded at $9.485, with a volume of 481.20K.
It is down -0.37% in the last 24 hours and up +25.63% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$9.52
Open:
$9.59
24h Volume:
481.20K
Relative Volume:
0.09
Market Cap:
$2.06B
Revenue:
$51.95M
Net Income/Loss:
$-265.94M
P/E Ratio:
-6.5941
EPS:
-1.4384
Net Cash Flow:
$-216.89M
1W Performance:
+1.77%
1M Performance:
+25.63%
6M Performance:
-17.74%
1Y Performance:
+16.67%
1-Day Range:
$9.48
$9.75
1-Week Range:
$9.36
$9.955
52-Week Range:
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
9.485 | 2.07B | 51.95M | -265.94M | -216.89M | -1.4384 |
VRTX
Vertex Pharmaceuticals Inc
|
430.89 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.59 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
784.30 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.80 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.44 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
May 5 at 8 a.m. ET: Ocular Therapeutix to discuss Q1 results - Stock Titan
Ocular Therapeutix gains amid takeover speculation - MSN
OCUL stock surges overnight ahead of crucial wet AMD data readout, Sanofi takeover buzz builds - MSN
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data - Yahoo Finance
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences - The Manila Times
Ocular lines up May talks on AMD trial data and investor webcasts - Stock Titan
Ocular Therapeutix prices $475M stock offering - MSN
Avoiding Lag: Real-Time Signals in (OCUL) Movement - Stock Traders Daily
Ocular Therapeutix (OCUL) Is Up 8.2% After Positive Phase 3 AXPAXLI Data and FDA FeedbackWhat's Changed - Sahm
Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates - Sahm
Ocular Therapeutix (OCUL) Quarterly Preview | Q4 2025: Profit SurprisesRevenue Diversification - Xã Thanh Hà
OCUL (Ocular Therapeutix Inc.) reports narrower Q4 2025 loss than consensus estimates, driving a 10.84 percent one-day share rally.Social Investment Platform - Cổng thông tin điện tử tỉnh Tây Ninh
OCUL (Ocular Therapeutix Inc.) tops Q4 2025 EPS estimates, shares gain slightly even as quarterly revenue declines year over year.Earnings Quality - Cổng thông tin điện tử Tỉnh Sơn La
Ocular Therapeutix lines up senior leaders, retina experts for June 17 - Stock Titan
Ocular Therapeutix (OCUL) soars 10.4% ahead of business updates - MSN
Ocular Therapeutix releases additional phase 3 AXPAXLI data for wet AMD - Eyes On Eyecare
Ocular Therapeutix Reports Positive Trial Data for Macular Degeneration - HarianBasis.co
Ocular Therapeutix Data Strengthens AXPAXLI Durability Case And FDA Ambitions - Sahm
Ocular Therapeutix Hits Day High with Strong 10.84% Intraday Surge - Markets Mojo
Ocular Therapeutix Experiences Revision in Its Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
HC Wainwright lifts Ocular Therapeutix, Inc. (OCUL) price target following intravitreal implant FDA submission - MSN
Ocular Therapeutix (OCUL) Stock Short Interest Analysis (Underperforming) 2026-04-20Smart Money Flow - Xã Thanh Hà
Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI - Insider Monkey
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix Stock Soars to Day High with 10.45% Surge - Markets Mojo
Ocular Therapeutix (NASDAQ:OCUL) Trading 10.2% HigherHere's What Happened - MarketBeat
Here is why Ocular Therapeutix (OCUL) is highly favored by hedge funds - MSN
Is It Time To Reconsider Ocular Therapeutix (OCUL) After Its Recent Share Price Swings? - Sahm
Discipline and Rules-Based Execution in OCUL Response - Stock Traders Daily
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study - Sahm
H.C. Wainwright reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
New Ocular SVP gets 300,000 stock options in inducement grant - Stock Titan
Aug EndMonth: Can Ocular Therapeutix Inc maintain its current growth rateWeekly Gains Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Large Ocular Therapeutix (OCUL) share gift to spouse disclosed - Stock Titan
William Blair reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
Ocular Therapeutix Inc Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD - marketscreener.com
Ocular Therapeutix presents additional wet AMD trial data By Investing.com - Investing.com Australia
William Blair Maintains Ocular Therapeutix(OCUL.US) With Buy Rating - Moomoo
OCUL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $21 - GuruFocus
What's Going On With Ocular Therapeutix Stock Monday?Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
HC Wainwright Reiterates "Buy" Rating for Ocular Therapeutix (NASDAQ:OCUL) - MarketBeat
Positive Week 52 Data Released for Ocular Therapeutix (OCUL) - GuruFocus
Is Ocular Therapeutix (OCUL) Quietly Recasting Its Retinal Strategy Around Axpaxli’s Phase 3 Design Choices? - Yahoo Finance
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD - The Manila Times
Ocular Therapeutix Presents New SOL-1 Data Reinforcing AXPAXLI's Efficacy and Durability in Wet AMD at VBS Meeting - Quiver Quantitative
Ocular Therapeutix presents additional wet AMD trial data - Investing.com
Ocular Therapeutix™ Announces Additional Positive Week 52 - GlobeNewswire
Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD - Bitget
Assessing Whether Ocular Therapeutix (OCUL) Looks Undervalued After Recent Mixed Share Price Performance - Yahoo Finance
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ocular Therapeutix Inc Stock (OCUL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kaiser Peter | Chief Development Officer |
Feb 23 '26 |
Sale |
8.28 |
2,810 |
23,267 |
269,108 |
| Heier Jeffrey S. | Chief Scientific Officer |
Feb 23 '26 |
Sale |
8.28 |
3,057 |
25,312 |
323,368 |
| Nayak Sanjay | Chief Strategy Officer |
Feb 23 '26 |
Sale |
8.28 |
1,759 |
14,565 |
330,653 |
| Waheed Nadia | Chief Medical Officer |
Feb 20 '26 |
Sale |
7.74 |
3,510 |
27,167 |
314,907 |
| LINDSTROM RICHARD L MD | Director |
Feb 20 '26 |
Buy |
7.66 |
60,229 |
461,354 |
246,933 |
1.05%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):